CatalystMarker
← board

FBLG

FibroBiologicsdistress 8/10 · high distress / dilution risk
$0.74+0%today-95% from 52w high
fibrobiologics.com15 employeesFounded 2021Houston, TXBiotechnology
Metabolic / Obesity 1
Lead: Diabetic Foot Ulcer (DFU)
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
-88%

Price & events

-89.1% over 6M
$0.73$4.72$8.70Jan 26Apr 26Jul 268.9Mdilution: 424B3 offering (2026-07-16)dilution: EFFECT shelf_effective (2026-07-16)dilution: S-3 shelf_registration (2026-07-10)dilution: 424B5 offering (2026-05-06)dilution: 424B5 offering (2026-05-01)dilution: 424B4 offering (2026-04-01)dilution: EFFECT shelf_effective (2026-03-31)dilution: S-1 shelf_registration (2026-03-27)financing: 8-K private_placement (2026-06-29)financing: 8-K material_agreement (2026-05-06)financing: 8-K material_agreement (2026-05-01)financing: 8-K material_agreement (2026-04-09)financing: 8-K material_agreement (2026-04-02)catalyst: PHASE1,PHASE2 SoC + Low dose CYWC628, SoC + High dose CYWC628 (2026-03-01) — click to openrating: Maxim Group: Buy → Hold (2026-05-04)rating: HC Wainwright & Co.: Buy (2026-04-16)rating: D. Boral Capital: Buy → Hold (2026-03-26)rating: D. Boral Capital: Buy (2026-03-12)rating: HC Wainwright & Co.: Buy (2026-02-26)rating: D. Boral Capital: Buy (2026-02-25)
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
-11.5%
1W
-0.9%
1M
-50.8%
3M
-90.7%
6M
-94.4%
1Y
-99.2%
2Y
—
5Y
-99.9%
All

Overview

Market Cap
$3.87M
Volume
3.04K
52 Week Range
$0.73 – $14.34
Total Shares
5.21M
Float Shares
4.57M
Short %
2.78%
% Held by Insiders
12.62%
% Held by Institutions
12.51%
RVOL
0.02x
Beta
1.17

Pipeline stages · 1 programs

SoC + Low dose CYWC628, SoC + High dose CYWC628
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 1 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-03
Phase 1/2SoC + Low dose CYWC628, SoC + High dose CYWC628Diabetic Foot Ulcer (DFU)120not yet recruiting

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 5,208,915 · 8 offerings/1y · 4 PIPEs
  • 2026-07-16EFFECTshelf_effective
  • 2026-07-16424B3offering
  • 2026-07-10S-3shelf_registration
  • 2026-06-298-Kprivate_placement
  • 2026-05-068-Kmaterial_agreement
  • 2026-05-06424B5offering
  • 2026-05-018-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-05-04Maxim GroupBuy → Hold
  • 2026-04-16HC Wainwright & Co.Buy
  • 2026-03-26D. Boral CapitalBuy → Hold
  • 2026-03-12D. Boral CapitalBuy
  • 2026-02-26HC Wainwright & Co.Buy
  • 2026-02-25D. Boral CapitalBuy

Competitors — Diabetic Foot Ulcer (DFU)

  • none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.